Skip to content
10-Q

Quarterly Report

Cyteir Therapeutics, Inc.

0000950170-23-020510

← back to feed
Filed
May 10, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · May 4, 2023 35.51M sh
Shares Diluted Q1 2023 · Mar 31, 2023 35.59M sh
Shares Diluted Q1 2023 · Mar 31, 2022 35.24M sh
Operating Cash Flow Q1 2023 · Mar 31, 2023 −$10.17M
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$12.17M
Cash And Equivalents Q1 2023 · Mar 31, 2023 $137.2M
Cash And Equivalents Q1 2023 · Dec 31, 2022 $147.12M
Cash And Equivalents Q1 2023 · Mar 31, 2022 $177.38M
Stockholders Equity Q1 2023 · Mar 31, 2023 $134.98M
Stockholders Equity Q1 2023 · Dec 31, 2022 $146.29M
Stockholders Equity Q1 2023 · Mar 31, 2022 $174.5M
Stockholders Equity Q1 2023 · Dec 31, 2021 $187.29M
Current Liabilities Q1 2023 · Mar 31, 2023 $3.96M
Current Liabilities Q1 2023 · Dec 31, 2022 $5.32M
Total Liabilities Q1 2023 · Mar 31, 2023 $4M
Total Liabilities Q1 2023 · Dec 31, 2022 $6.95M
Current Assets Q1 2023 · Mar 31, 2023 $138.39M
Current Assets Q1 2023 · Dec 31, 2022 $149.21M
Total Assets Q1 2023 · Mar 31, 2023 $138.98M
Total Assets Q1 2023 · Dec 31, 2022 $153.23M
Eps Diluted Q1 2023 · Mar 31, 2023 −$0.35
Eps Diluted Q1 2023 · Mar 31, 2022 −$0.40
Eps Basic Q1 2023 · Mar 31, 2023 −$0.35
Eps Basic Q1 2023 · Mar 31, 2022 −$0.40
Sga Expense Q1 2023 · Mar 31, 2023 $4.11M
Sga Expense Q1 2023 · Mar 31, 2022 $4.04M
Rd Expense Q1 2023 · Mar 31, 2023 $9.31M
Rd Expense Q1 2023 · Mar 31, 2022 $10.09M
Net Income Q1 2023 · Mar 31, 2023 −$12.49M
Net Income Q1 2023 · Mar 31, 2022 −$14.1M
Operating Income Q1 2023 · Mar 31, 2023 −$13.42M
Operating Income Q1 2023 · Mar 31, 2022 −$14.13M
Capex Q1 2023 · Mar 31, 2022 $191K